EverSource Wealth Advisors’s Arcus Biosciences RCUS Stock Holding History

EverSource Wealth Advisors’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.49K	Sell	178 -139	-44%	-$3.44K	﹤0.01%	3240
2026 Q1	$6.85K	Sell	317 -120	-27%	-$2.59K	﹤0.01%	3109
2025 Q4	$10.4K	Hold	437	–	–	﹤0.01%	2773
2025 Q3	$5.94K	Buy	437 +133	+44%	+$1.38K	﹤0.01%	3081
2025 Q2	$2.48K	Buy	304 +289	+1,927%	+$2.47K	﹤0.01%	3434
2025 Q1	$118	Sell	15 -6	-29%	-$70	﹤0.01%	3803
2024 Q4	$313	Buy	21 +13	+163%	+$212	﹤0.01%	3334
2024 Q3	$122	Buy	+8	New	+$126	﹤0.01%	2975
2024 Q1	–	Sell	-108	Closed	-$2.06K	–	2975
2023 Q4	$2.06K	Buy	+108	New	+$1.73K	﹤0.01%	2153

Other funds holding RCUS

Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

EverSource Wealth Advisors's RCUS Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its Arcus Biosciences (RCUS) stake by 44% in Q2 2026, selling an estimated $3.44K and leaving 178 shares worth $5.49K. The position accounts for ﹤0.01% of the portfolio, ranked #3240.

EverSource Wealth Advisors first reported a position in RCUS in Q4 2023 and has held it in 9 quarters since. The position peaked at $10.4K in Q4 2025. 231 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

EverSource Wealth Advisors held 178 shares of Arcus Biosciences worth $5.49K as of Q2 2026.
EverSource Wealth Advisors sold 139 Arcus Biosciences shares in Q2 2026, an estimated $3.44K.
Arcus Biosciences made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #3240 holding.
EverSource Wealth Advisors first reported a position in Arcus Biosciences in Q4 2023 and has held it in 9 quarters since.
EverSource Wealth Advisors's Arcus Biosciences position peaked at $10.4K in Q4 2025.
231 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.